Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$5.89 USD
-0.15 (-2.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.76 -0.13 (-2.21%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALDX 5.89 -0.15(-2.48%)
Will ALDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Other News for ALDX
Biotech Alert: Searches spiking for these stocks today
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Aldeyra Therapeutics Announces Executive Team Changes
Undercovered Dozen: United Natural Foods, Procter & Gamble, Archer Aviation, Embraer +
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership